Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the primary care segment. It markets medicines in the areas of orphan diseases, rheumatology and primary care. The majority of revenue is generated in the United States.
| Website: | www.horizonpharma.com |
| Email: | investor-relations@horizonpharma.com |
| Main Phone: | +353 17722100 |
| Address: | 1 Burlington Road |
| Address 2: | Connaught House, 1st Floor |
| City / Town: | Dublin 4 |
| Country: | IRL |
| Postal Code: | D04 C5Y6 |
| Exchange: | NGS |
| CEO: | Timothy P. Walbert |
| Employees: | 1175 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Four stocks positioned right at key technical breakout points.
The presidential race continues to heat up while Apple (AAPL) had a huge week and the company you buy aspirin from bought the company you blame for most of the country's problems.
Last week, shares of pharma roll-up firm Valeant Pharmaceuticals (VRX), which had already been punished in September’s health-care rout, were slammed by accusations of fraud made by
Life sciences analyst Daniel Pearlstein of Toronto-based M Partners brings knowledge of the biotech sector and hands-on experience in the startup realm to understanding value and growth in small-
Picking small-cap health care stocks can be a pretty iffy endeavor. With the science unclear until the results of various clinical trials, it’s extremely difficult to get a reliable
It’s been a tough year for small-cap companies thus far in 2014. The recent market pullback hit growth companies hard as investors appeared to be interested in reducing the risk profile of
Diversified manufacturer Honeywell Intl Inc. (HON) reported on Friday that its profits in the first quarter grew by 17 percent even though sales were essentially flat as its cost-cutting efforts
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the primary care segment. It markets medicines in the areas of orphan diseases, rheumatology and primary care. The majority of revenue is generated in the United States.
| Website: | www.horizonpharma.com |
| Email: | investor-relations@horizonpharma.com |
| Main Phone: | +353 17722100 |
| Address: | 1 Burlington Road |
| Address 2: | Connaught House, 1st Floor |
| City / Town: | Dublin 4 |
| Country: | IRL |
| Postal Code: | D04 C5Y6 |
| Exchange: | NGS |
| CEO: | Timothy P. Walbert |
| Employees: | 1175 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Four stocks positioned right at key technical breakout points.
The presidential race continues to heat up while Apple (AAPL) had a huge week and the company you buy aspirin from bought the company you blame for most of the country's problems.
Last week, shares of pharma roll-up firm Valeant Pharmaceuticals (VRX), which had already been punished in September’s health-care rout, were slammed by accusations of fraud made by
Life sciences analyst Daniel Pearlstein of Toronto-based M Partners brings knowledge of the biotech sector and hands-on experience in the startup realm to understanding value and growth in small-
Picking small-cap health care stocks can be a pretty iffy endeavor. With the science unclear until the results of various clinical trials, it’s extremely difficult to get a reliable
It’s been a tough year for small-cap companies thus far in 2014. The recent market pullback hit growth companies hard as investors appeared to be interested in reducing the risk profile of
Diversified manufacturer Honeywell Intl Inc. (HON) reported on Friday that its profits in the first quarter grew by 17 percent even though sales were essentially flat as its cost-cutting efforts
| Last Price 35.50 | Change $ -0.54 | Change % -1.50 | Tick N/A |
| Bid 34.00 | Bid Size 100.00 | Ask 36.63 | Ask Size 100.00 |
| Open 35.99 | High 36.00 | Low 34.75 | Prev Close 36.04 |
| Last Trade | Volume 1.6 mi | 52 Wk Hi 39.10 | 52 Wk Low 20.05 |
| Market Cap 6.6 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 187,302,229.00 | EPS (TTM) 0.26 | PE Ratio 138.60 | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 36 | 64 |
| Number of Buys | 18 | 32 |
| Number of Sells | 18 | 32 |
| Net Activity | 242822 | 343770 |
| Last 10 Buys | Shares |
|---|---|
| Michael G. Grey | 1,000 |
| H. Thomas Watkins | 1,000 |
| H. Thomas Watkins | 1,000 |
| Jeffrey W. Bird | 1,000 |
| Jeffrey W. Bird | 1,000 |
| Jeffrey W. Bird | 1,000 |
| Jeffrey W. Bird | 1,000 |
| Jeffrey W. Bird | 1,000 |
| Jeffrey W. Bird | 1,000 |
| Jeffrey W. Bird | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Brian K. Beeler | 1,000 |
| Brian K. Beeler | 1,000 |
| Timothy P. Walbert | 1,000 |
| Brian K. Beeler | 1,000 |
| Robert F. Carey | 1,000 |
| Robert F. Carey | 1,000 |
| Jeffrey W. Sherman | 1,000 |
| Virinder Nohria | 1,000 |
| Jeffrey W. Sherman | 1,000 |
| Jeffrey W. Sherman | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 24 | 24 | 24 | 24 |
| Low Target Price Estimate | 16 | 16 | 16 | 16 |
| Mean Target Price Estimate | 20 | 20 | 20 | 20 |
| Standard Deviation | 3.21 | 3.21 | 3.21 | 3.21 |
| Date of Most Recent Estimate | 05/22/18 | 05/22/18 | 05/22/18 | 05/22/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-05 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-21 |
| CT ORDER | 1 | 2018-05-14 | |
| S-8 | Securities offered to employees under employee benefit plans | 10 | 2018-05-11 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 112 | 2018-05-09 |
| 8-K | Report of unscheduled material events or corporate changes. | 20 | 2018-05-09 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-07 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 1 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1.29 | 1.29 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait